Skip to main content

Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts).

Publication ,  Conference
Vogelzang, NJ; Vacirca, JL; Kantoff, PW; Scholz, MC; Dakhil, SR; Nordquist, LT; Higano, CS; Sartor, AO; Cooperberg, MR; Sandler, A; McCoy, C ...
Published in: Journal of Clinical Oncology
February 1, 2014

185 Background: Sip-T is an autologous cellular immunotherapy indicated for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). PROCEED is an ongoing phase 4 registry, enrolling pts receiving commercial sip-T. There are no exclusions based on prior prostate cancer treatments, so sip-T product parameters can be evaluated in pts receiving prior hormonal agents such as ABI or ENZ. Methods: Pts treated with sip-T within ≤6 mo were eligible to provide informed consent. Prior anticancer interventions were recorded at baseline. Sip-T product parameters were assessed. Results: Of 1,376 pts (as of May 2013), 108 (7.8%) received prior ABI and 58 (4.2%) received ENZ. Patients with ABI or ENZ generally had more advanced disease vs. pts without prior ABI or ENZ (WPT) and a greater proportion of the ABI and ENZ pts received prior docetaxel. There were slight differences in some sip-T product parameters in the ABI and ENZ groups, but neither manufacture nor receipt of sip-T were inhibited, as indicated by the percentage of pts with 3 successful infusions. All groups showed evidence of immune prime boost (Table). Conclusions: A subset of patients in PROCEED have received ABI or ENZ prior to sip-T. We observed no impact of prior ABI/ENZ on sip-t manufacturing or delivery, despite these men having more advanced disease. These results are consistent with prior analyses demonstrating a positive sip-T treatment immune effect in patients who have received prior therapies, including chemotherapy. Further immune monitoring and outcome studies are currently ongoing in the pre-docetaxel mCRPC setting where these agents will likely be used clinically. Clinical trial information: NCT01306890. [Table: see text]

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 1, 2014

Volume

32

Issue

4_suppl

Start / End Page

185 / 185

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vogelzang, N. J., Vacirca, J. L., Kantoff, P. W., Scholz, M. C., Dakhil, S. R., Nordquist, L. T., … Armstrong, A. J. (2014). Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts). In Journal of Clinical Oncology (Vol. 32, pp. 185–185). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.4_suppl.185
Vogelzang, Nicholas J., Jeffrey L. Vacirca, Philip W. Kantoff, Mark C. Scholz, Shaker R. Dakhil, Luke T. Nordquist, Celestia S. Higano, et al. “Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts).” In Journal of Clinical Oncology, 32:185–185. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.4_suppl.185.
Vogelzang NJ, Vacirca JL, Kantoff PW, Scholz MC, Dakhil SR, Nordquist LT, et al. Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 185–185.
Vogelzang, Nicholas J., et al. “Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts).Journal of Clinical Oncology, vol. 32, no. 4_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 185–185. Crossref, doi:10.1200/jco.2014.32.4_suppl.185.
Vogelzang NJ, Vacirca JL, Kantoff PW, Scholz MC, Dakhil SR, Nordquist LT, Higano CS, Sartor AO, Cooperberg MR, Sandler A, McCoy C, Whitmore JB, Tyler RC, Armstrong AJ. Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 185–185.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 1, 2014

Volume

32

Issue

4_suppl

Start / End Page

185 / 185

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences